To further investigate the immune landscape of PBRM1-deficient tumors, we stained a TMA from 20 RCC patients without prior treatment, including 15 samples with wild-type PBRM1 and 5 with PBRM1 mutations, and each sample was triplicated. This evidence concerns the gene PBRM1 and renal cell carcinoma.